Assessment of Tyrosine Kinase Inhibitors and Survival and Cardiovascular Outcomes of Patients With Non–Small Cell Lung Cancer in Taiwan

IMPORTANCE: Tyrosine kinase inhibitors (TKIs) have been recognized as the standard treatment for patients with non–small cell lung cancers (NSCLCs) and epidermal growth factor receptor (EGFR) sequence variation. Although TKIs have been reported to cause cardiotoxicity, they are widely administered o...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Wei-Ting, Lin, Hui-Wen, Chang, Ting-Chia, Lin, Sheng-Hsiang, Li, Yi-Heng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193184/
https://www.ncbi.nlm.nih.gov/pubmed/37195663
http://dx.doi.org/10.1001/jamanetworkopen.2023.13824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193184/
https://www.ncbi.nlm.nih.gov/pubmed/37195663
http://dx.doi.org/10.1001/jamanetworkopen.2023.13824

Ejemplares similares